Oppenheimer Reiterates Perform Rating on Rhythm Pharmaceuticals (RYTM)
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated a Perform rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented: "3Q26 Imcivree sales of $92.1M ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




